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The yeasts constitute a large and heterogeneous group of microorganisms that are currently
attracting increased attention from scientists and industry. Numerous and diverse biological
activities make them promising candidates for a wide range of applications not limited to
the food sector. In addition to their major contribution to flavor development in fermented
foods, their antagonistic activities toward undesirable bacteria, and fungi are now widely
known. These activities are associated with their competitiveness for nutrients, acidifica-
tion of their growth medium, their tolerance of high concentrations of ethanol, and release
of antimicrobial compounds such as antifungal killer toxins or “mycocins” and antibacterial
compounds. While the design of foods containing probiotics (microorganisms that con-
fer health benefits) has focused primarily on Lactobacillus and Bifidobacterium, the yeast
Saccharomyces cerevisiae var. boulardii has long been known effective for treating gas-
troenteritis. In this review, the antimicrobial activities of yeasts are examined. Mechanisms
underlying this antagonistic activity as well as recent applications of these biologically active
yeasts in both the medical and veterinary sectors are described.
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INTRODUCTION
The term“yeast”was derived originally from the Dutch word“gist,”
which refers to the foam formed during the fermentation of beer
wort. Other words referring to yeast, such as the French word “lev-
ure,” refer to the role of yeast in causing bread dough to rise. Few
other microbial organisms match the yeasts in terms of histori-
cal, economic, and scientific significance. In addition to their role
in the production of fermented foods and beverages, the yeasts
play various roles in livestock feeding and veterinary practices as
well as in medicine and the biomedical and pharmaceutical indus-
tries. One of these roles consists primarily of antagonizing other
microorganisms such as undesirable yeasts, molds, and bacteria.
The inhibitory activity of yeast was discovered first by Hayduck
(1909). Somewhat later, other researchers reported the antagonis-
tic action of yeasts against other yeasts, involving the production
of secondary metabolites known as killer toxins or “mycocins”
(Young and Yagiu, 1978; Rosini and Cantini, 1987; Walker et al.,
1995; Suzuki et al., 2001; Marquina et al., 2002). In summariz-
ing the antimicrobial effects of yeasts present in fermented foods
and beverages, Viljoen (2006) mentions actions of organic acids,
antibiotic factors, volatile acids, hydrogen peroxide, and various
other substrates excreted in the product. However, there has been
relatively little study devoted to identifying the mechanisms of
inhibition by yeasts.
In this chapter, the metabolic factors mentioned above as well
as recent advances in knowledge of the antagonistic properties of
yeasts will be discussed, with emphasis on the potential oppor-
tunities for application in various fields. Although only Saccha-
romyces cerevisiae var. boulardii has been studied in detail and
its inhibitory mechanisms well defined, significant antagonistic
activities have been associated with several other genera or species,
and exploration of their potential industrial and biotechnological
applications is expected.
YEASTS
GENERAL CONSIDERATION AND TAXONOMY
The yeasts described in this review are all members of the phylum
Ascomycota and the class Saccharomycota. Phylogenetic analysis
of the phylum Ascomycota has significantly changed yeast clas-
sification in recent years (Hibbett et al., 2007; Kurtzman et al.,
2011a,b). Yeasts are eukaryotic microorganisms widespread in
natural environments including the normal microbial flora of
humans, on plants, on airborne particles, in water, in food prod-
ucts, and in many other ecological niches. Yeasts are important in
many complex ecosystems,as frequent early colonizers of nutrient-
rich substrates (Kurtzman et al., 2011a,b). They are involved in
many interactions with other microorganisms, including sym-
biosis, mutualism, parasitism, and competition. They also exhibit
both asexual and sexual states. The asexual state of given yeast is
called the anamorph, while the sexual state is the teleomorph. One
result of this phenomenon is that there is a valid Latin name for
each state, since no teleomorph has been found for many asexual
forms or because the phylogenetic relationship between anamorph
and teleomorph has not been confirmed.
The most common mode of vegetative growth of yeasts is
by budding, which may be blastic or thallic. Anamorphic and
teleomorphic genera may grow either as a “yeast-like” unicellular
organism or as a “mold-like” filamentous organism, a phenome-
non called dimorphism. Moreover, some species are able to form
a true mycelium, while genera such as Candida produce a well-
developed pseudomycelium, or both pseudo and true mycelium
in the case of Candida tropicalis (Goldman, 2008).
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Among the yeasts belonging to the phylum Ascomycota, the
genus Saccharomyces is the most studied. Many of the approx-
imately 20 species of this genus are of great biotechnological
significance due to applications including alcoholic fermentation,
bread-making, single cell protein, vitamin production, synthesis of
recombinant proteins, and biological control (Webster and Weber,
2007). The most significant species is certainly S. cerevisiae (baker’s
and brewer’s yeast), due to its economic impact. S. cerevisiae is
used for the annual production of an estimated 60 million tons
of beer, 30 million tons of wine, 800,000 tons of single cell pro-
tein, and 600,000 tons of baker’s yeast (Pretorius et al., 2003). The
vegetative cells of S. cerevisiae are normally diploid, but some
strains have been reported as aneuploid or tetraploid (Webster
and Weber, 2007). Over the past four decades, a yeast first identi-
fied as Saccharomyces boulardii has been studied for its potential
probiotic use (Buts, 2009). The taxonomic position of S. boulardii
was determined using multi locus sequence analysis targeting the
D1/D2 domain of the 26S rDNA subunit, the ITS1-5.8S rDNA-
ITS2 sequence, and the mitochondrial cytochrome C oxidase II
(COX2) gene. Each locus is highly similar to the corresponding loci
in S. cerevisiae, which led to the proposal to assimilate S. boulardii
into the S. cerevisiae species (Van Der Aa Kühle and Jespersen,
2003). The denomination S. cerevisiae var. boulardii has been pro-
posed, but the designation S. boulardii is still largely used in the
scientific literature.
YEAST METABOLISM
Yeasts are heterotrophic organisms, meaning that energy metab-
olism and carbon metabolism are intimately interconnected.
Adenosine triphosphate (ATP) is provided by oxidation of organic
molecules that also act as carbon sources for biosynthesis, and is
ultimately used as the energetic intermediate for practically all cel-
lular activities (Rodrigues et al., 2006). Yeasts have relatively sim-
ple nutritional requirements, a carbon source, a nitrogen source
(ammonium salt, nitrate, amino acids, peptides, urea, purines,
pyrimidines), phosphate, sulfate, lower concentrations of potas-
sium, magnesium, calcium, iron, zinc, and in most cases a vitamin
such as biotin, thiamine, or pantothenic acid making up a com-
plete growth medium. It is well known that the principal carbon
source employed by yeasts is carbohydrate, primarily hexose sug-
ars as monosaccharides (glucose, fructose, galactose, or mannose)
or disaccharides (maltose or sucrose). In addition, a wide range of
other carbon sources (e.g., alcohols, organic acids) can be utilized
under aerobic conditions (Deak, 2006).
Van Dijken and Scheffers (1986) classified yeasts physiologi-
cally according to the type of energy-generating process involved
in sugar metabolism, namely non-fermentative, facultatively fer-
mentative, or obligately fermentative. It was later found that
basidiomycetous yeasts such as Cryptococcus, Rhodotorula, and
others are non-fermentative and strictly aerobic (Goldman, 2008).
Not even the obligate fermentative species can survive for very
long under strict anaerobic conditions, since the synthesis of cer-
tain membrane constituents (i.e., sterols) requires oxygen (Deak,
2006). Yeast metabolism and physiology are thus strongly depen-
dent on sugar and oxygen availability. Yeast aerobic respiration
has been defined by Dawes (1986) as the complete oxidation of
carbon-containing molecules to CO2 and H2O by the interrelated
processes of the tricarboxylic acid (TCA) cycle and the electron
transport chain coupled to phosphorylation with oxygen as the
terminal electron acceptor. In yeast anaerobic metabolism, often
called “alcoholic fermentation,” pyruvate produced by glycolysis is
split into ethanol and CO2 in a redox-neutral process (Van Dijken
and Scheffers, 1986).
Finally, there are three frequently observed effects associated
with the type of energy-generating processes involved in sugar
metabolism and/or oxygen availability; Pasteur, Cabtree, and
Custer effect (Van Dijken and Scheffers, 1986; Fredlund et al., 2004;
Dickinson and Kruckeberg, 2006; Wijsman et al., 1984). Due to its
industrial importance, better understanding of yeast metabolism
is needed in order to provide insight into the formation of primary
and secondary metabolites and their impact on human health.
ANTAGONISTIC CHARACTERISTICS OF YEASTS
The use of antagonistic bacteria to inhibit pathogenic bacteria has
been studied extensively over the years, while little attention has
been given to yeasts in a similar role. The study and potential appli-
cations of antibacterial compounds secreted by yeasts are therefore
still at an early stage of development.
Antagonism of microorganisms by yeasts has been attributed
primarily to (1) competition for nutrients, (2) pH changes in the
medium as a result of growth-coupled ion exchange or organic
acid production, (3) production of high concentrations of ethanol,
(4) secretion of antibacterial compounds and release of antimi-
crobial compounds such as killer toxins or “mycocins” (Suzuki
et al., 2001; Golubev, 2006; Young and Yagiu, 1978). Mycocins
are extracellular proteins or glycoproteins that disrupt cell mem-
brane function in susceptible yeasts, which bear receptors for the
compound (Golubev, 2006). Their activity is directed primarily
against yeasts closely related to the producer strain, which has
a protective factor. The first mycocins were identified in asso-
ciation with S. cerevisiae in the brewing industry (Bevan and
Somers, 1969). Several have since been isolated, frequently where
yeast populations exist in high density and in highly competi-
tive conditions. Mycocin production occurs among many yeast
genera including Saccharomyces, Candida, Cryptococcus, Debary-
omyces, Kluyveromyces, Pichia, Torulopsis, Williopsis, and Zygosac-
charomyces (Young and Yagiu, 1978; Magliani et al., 1997; Chen
et al., 2000; Schmitt and Breinig, 2002; Golubev, 2006; Hodgson
et al., 1995). Genetic and molecular studies have shown that the
killer toxin trait may be carried on extra-chromosomal elements
in the form of double-stranded RNA viruses (Wickner, 1996), on
double-stranded linear DNA (Gunge et al., 1981; Hayman and
Bolen, 1991), or on a chromosome (Kimura et al., 1993; Suzuki
and Shimma, 1999). The well known mechanisms of the killer
toxin are the interruption of cell division by blocking the DNA
synthesis, inhibition of synthesis of the cell wall component β-
1,3-glucan (Izgu and Altinbay, 2004), and ion leakage caused by
the formation of channels on the cytoplasmic membrane (Kagan,
1983; Schmitt and Breinig, 2002; White et al., 1989; Figure 1).
Unlike yeast-against-yeast antagonism, the antibacterial properties
of yeast are much less documented.
Historically, the first positive indications of the antagonistic
activity of yeasts published early in the twentieth century by Hay-
duck (1909) and Fernbach (1909; cited in Golubev, 2006) who
reported a volatile thermolabile toxic extract from yeast probably
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FIGURE 1 | Summary of the different aspects of antagonistic properties
of yeasts. (A) Competition for nutrients; (B) pH changes; (C) production of
high concentrations of ethanol; (D) killer toxins or mycocins; (E) mycocin
causes ion leakage by the formation of channels on the cytoplasmic
membrane; (F) mycocin inhibits the synthesis of cell wall component
β-1,3-glucan; (G) mycocin interrupts cell division by blocking the DNA
synthesis; (H) proteases degrade bacterial toxins; (I) stimulate the immune
response; (J) yeasts inhibit attachment to intestinal cells.
an amine that inhibits the growth of Escherichia coli and Staphy-
lococci (Viljoen, 2006). Fatichenti et al. (1983) showed that the
antibacterial activity of Debaryomyces hansenii against Clostrid-
ium tyrobutyricum and Clostridium butyricum was related to its
ability to produce both extracellular and intracellular antimicro-
bial compounds. Bilinski and Casey (1989) reported inhibition
of the growth of the beer spoilage bacteria Bacillus megaterium
and Lactobacillus plantarum due to the conversion of methylene
blue into a pharmacologically active form by Kloeckera apicu-
lata and Kluyveromyces thermotolerans. Dieuleveux et al. (1998)
subsequently described inhibition of Listeria by a strain of Geot-
richum candidum isolated from French red smear cheese. The two
anti-listerial compounds (d-3-phenyllactic and d-3-indollactic
acids) are stable over a wide pH range and can be heated to
120˚C for 20 min. Also, Cavalero and Cooper (2003) demonstrated
that Candida bombicola produces extracellular glycolipids called
sophorosides, which have proven antibacterial activity against
Staphylococcus aureus and also inhibit Candida albicans. Having
tested hundreds of dairy yeasts, Goerges et al. (2006) reported
a strain of Candida intermedia capable of reducing viable Liste-
ria counts by 4 log CFU/cm2 in co-culture on agar, while three C.
intermedia and one Kluyveromyces marxianus suppressed L. mono-
cytogenes growth by 3 log CFU/cm2. The same group more recently
found a strain of Pichia norvegensis (WSYC 592) able to reduce L.
monocytogenes counts by 7 log cycles, while numerous strains of
Issatchenkia orientalis, Candida krusei, and K. marxianus reduced
Listeria counts by 4–5 log units in co-culture on agar (Goerges et
al., 2011). However, strain WSYC 592 decreased Listeria counts on
Tilsit cheese by only one log cycle. More recently, Hatoum et al.
(2012) characterized anti-listerial hydrophobic peptides extracted
from cultures of four wild dairy yeasts identified as D. hansenii, P.
fermentans, C. tropicalis, and W. anomala. In experiments using
a Camembert curd model, the anti-listerial compounds of D.
hansenii and W. anomalus were found to reduce L. monocytogenes
counts by 3 log units during the first 9 days of ripening. The active
principles are thermostable and apparently peptides and appear
to induce leakage in bacterial cells and ultimately cause bacterial
lysis (Figure 2).
APPLICATIONS OF ANTAGONISTIC ACTIVITIES OF YEASTS
The discovery of antagonistic activities of yeasts has had a signifi-
cant impact in numerous fields such as food, agriculture, medicine,
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FIGURE 2 | (A,B)TEM micrographs showing Listeria monocytogenes
LMA-1045 after 1 min of contact with solvent extracts of
Wickerhamomyces anomalus LMA-827 (A) and Candida tropicalis LMA-693
(B) culture supernatants. PF – pore formation in cell membrane;
DC – digested cell. Grids were examined at 80 kV. The magnification factor
is 30,000×. Bars indicate 0.5µm.
veterinary medicine, environmental protection, and others. The
following sections of this paper provide an updated summary of
published findings regarding the antagonistic properties of yeasts.
Figure 3 presents an organogram in which the applications are
grouped in three different clouds in a free-mind program http:
//bactibase.pfba-lab-tun.org/freemind/. The articles are linked to
these three clouds.
FOOD AND AGRICULTURE
Processed food and beverages applications
The past decades have witnessed the application of antagonis-
tic yeast starter cultures in various food processing industries.
It is well known that final product quality in industries such as
wine-making, sausage production, cheese ripening, bakery, and
the “fermentations” of cacao and coffee beans is affected directly
by the development of spoilage microorganisms (Romano et al.,
2006;Viljoen,2006). Antagonistic yeasts starter cultures contribute
to product safety primarily by inhibiting pathogen growth during
fermentation, and to finish product sensory qualities and shelf-life
by inhibiting spoilage organisms.
Numerous studies have proposed the use of mycocin-
producing yeasts as starter cultures to prevent the growth of
spoilage yeast strains and secondary fermentation wines (Hara
et al., 1980; Pfeiffer and Radler, 1984; Boone et al., 1990; Van
Vuuren and Jacobs, 1992; Comitini et al., 2004a,b; Seki et al.,
1985). A wine starter culture such as S. cerevisiae is normally able
to dominate native yeasts in the grape must during fermentation
(Pretorius, 2000). Also, in the production of sparkling wine, Todd
et al. (2000) studied the behavior of two sensitive strains of S.
cerevisiae in the presence of a mixture of two K2 killer toxin. The
authors concluded that this interaction accelerates the yeast autol-
ysis and per consequence the release of proteins that affects the
end product quality. Although S. cerevisiae strains that produce
K2 toxins have been found effective for preventing the growth
of spoilage yeast strains (Pfeiffer and Radler, 1984; Van Vuuren
and Jacobs, 1992), numerous non-Saccharomyces yeasts present
on the surface of grapes are insensitive to the S. cerevisiae killer
toxins. Killer toxins secreted by Kluyveromyces phaffii (KpKt) are
strong inhibitors of Hanseniaspora uvarum (Ciani and Fatichenti,
2001; Michalcáková et al., 1993) and thus appeared to have bio-
preservative properties potentially useful for the wine industry.
Years later, Comitini et al. (2004a,b) purified and characterized
a glycosylated 33 KDa protein produced by K. phaffii and found
that it binds to β-1,3-glucan, causing the formation of pores in the
cell walls of wine spoilage yeasts. They also showed that killer tox-
ins secreted by W. anomalus and Kluyveromyces wickeramii inhibit
Dekkera and Brettanomyces, spoilage yeasts that cause unpleas-
ant odors in wine. Numerous studies have confirmed remarkable
inhibitory properties of the killer toxin NCYC 432 (49 kDa glycosy-
lated peptide) of W. anomalus and the mycosin HMK of Williopsis
markii (Ibeas et al., 1996; Izgu and Altinbay, 2004; Izgu et al.,
2006; Lowes et al., 2000) against a wide range of pathogenic and
spoilage fungi. The antagonistic properties of yeast can also influ-
ence the interactions of wine yeast and malolactic bacteria mainly
Oenococcus oeni. In particular, this interaction between yeast and
bacteria can stimulate or prevent the progress of malolactic fer-
mentation which improves wine stability and quality (Alexandre
et al., 2004).
Applications of the mycocin-producing yeasts have been sug-
gested also for olive fermentation (Llorente et al., 1997; Asehraou
et al., 2007; Hernández et al., 2008; Marquina et al., 1992); beer
production (Young, 1981) sake production (Yoshiuchi et al., 2000),
and in salted fermented foods such as miso, soy sauce, and salted
vegetables (Kono and Himeno, 1997; Suzuki et al., 2001). It
has been reported that the inhibitory activity of D. hansenii is
enhanced by the presence of NaCl (Llorente et al., 1997), which
enhance the cell membrane porosity. This phenomena has also
been reported in dough production (Almeida and Pais, 1996)
and bread (Bortol et al., 1986). Uses of mycocin-producing starter
yeasts to prevent spoilage in yogurt (Lowes et al., 2000; Liu and
Tsao, 2009b,c, 2010a,b), probiotic cheese (Jakobsen and Narvhus,
1996), and other foods (Palpacelli et al., 1991) have also received
attention.
In spite of their potential benefits in terms of food preser-
vation, mycocin-producing yeasts should be used with caution.
The strain might have a negative impact on end product qual-
ity, as has been observed for cheese (Valdés-Stauber et al., 1997;
Wyder and Puhan, 1999) and wine (Fleet, 2007). Some strains have
developed super killer toxins and their escape into the natural envi-
ronment could threaten other industrial fermentation processes
(Magliani et al., 2005). Given the wide range of biotechnologi-
cal applications of antagonistic yeasts, further studies are required
to standardize inoculation parameters and maximize end product
stability.
Bio-control in unprocessed foods
The antagonistic properties of yeasts have been used in numer-
ous promising agricultural applications as natural bio-control
agents, both as soil treatments and for preventing diseases in pre-
and post-harvest crops. In 1995, the USA environmental pro-
tection agency registered Candida oleophila as bio-control post-
harvest yeast (El-neshawy and Wilson, 1997). This application has
been discussed in numerous studies (Walker et al., 1995; Lowes
et al., 2000; Masih et al., 2001; Masih and Paul, 2002; Santos
and Marquina, 2004; Spadaro and Gullino, 2004; Kitamoto et al.,
1999).
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MEDICAL APPLICATIONS
Probiotics
One of the most significant non-process uses of yeasts is as pro-
biotic microorganisms. The Food and Agriculture Organization
(FAO) of the World Health Organization (WHO) defines probi-
otics as “live microorganisms which when administered in ade-
quate amounts confer a health benefit on the host” (FAO/WHO,
2002). For many years, probiotics were used only in animal feeds.
Various authors have shown that surplus biomass from the fer-
mentation industry, recycled as an additive to cattle, hog, and
poultry diets, improves livestock performance and product quality
(Dawson et al., 1990; Li et al., 2006; van Heugten et al., 2003). It
was hypothesized that the yeast S. cerevisae provides vitamins B
and organic acids that stimulate the rumen acetogens (Chiquette,
2009) which form acetic acid (a utilizable form of carbon) from
hydrogen and carbon dioxide.
First isolated from litchi fruit in Indochina and described in
1984 as a saprophytic yeast, S. cerevisiae var. boulardii has emerged
as a probiotic species for human consumption (Van Der Aa Kühle
et al., 2005). This strain has also been recommended for the pre-
vention and treatment of several types of gastroenteritis in children
and adults (Kurugöl and Koturoglu, 2005; Htwe et al., 2008).
Nowadays, probiotic yeasts can be delivered either in fermented
foods or as lyophilized cultures administered orally, for exam-
ple, to patients who have been hospitalized as a consequence of
severe diarrhea. Several yeast species, including D. hansenii, Toru-
laspora delbrueckii (Psani and Kotzekidou, 2006), Kluyveromyces
lactis, Yarrowia lipolytica (Chen et al., 2010), K. marxianus, K. lod-
derae (Kumura et al., 2004) have been found strongly antagonistic
to pathogenic bacteria and to tolerate passage through the gas-
trointestinal tract. In a recent in vitro study, Etienne-Mesmin et al.
(2011) investigated the probiotic effect of S. cerevisiae CNCM I-
3856 against E. coli O157:H7. The results showed that the probiotic
yeast exert the antagonistic effects in the distal part of the small
intestine and that might be due to ethanol production. However,
only S. boulardii is considered as a probiotic (Czerucka et al., 2007).
Its probiotic efficiency has been well documented in numerous
clinical studies (Sazawal et al., 2006).
The text that follows describes the various mechanisms that
underlie the probiotic activities of S. boulardii against a variety
of pathogens such as Escherichia coli, Vibrio cholera, Clostridium
difficile, and Samonella in clinical and animal studies.
Antibiotic associated diarrhea “AAD”. Antibiotic therapy is well
known to destroy the normal bacterial population of the digestive
tract, which allows harmful bacteria to colonize and irritate the
host gut and cause antibiotic associated diarrhea (Coté and Buch-
man, 2006). Numerous placebo-controlled clinical studies have
shown the beneficial effects of S. boulardii in preventing antibi-
otic associated diarrhea (D’Souza et al., 2002; Erdeve et al., 2004;
Duman et al., 2005; Kotowska et al., 2005; Can et al., 2006; Cin-
doruk et al., 2007; Whelan, 2007; Bravo et al., 2008; Lewis et al.,
1998). In a double-blind study, Adam et al. (1976) reported a sig-
nificant reduction in AAD symptoms in the group that received
200 mg of S. boulardii (109 CFU/day) for 7 days. Only 4.5% of
this group developed AAD, compared to 17.5% of the placebo
group. In a study involving 193 hospitalized patients receiving
β-lactam antibiotics (Mcfarland et al., 1994), one group received
1 g of S. boulardii while the other was given a placebo, both
for periods lasting 3 days beyond the antibiotic treatment. AAD
appeared in 7.2% of the S. boulardii group compared to 14.6%
(P < 0.05) of the placebo group. In a study of the effect of 200 mg
of S. boulardii (109 CFU/day) for 2 weeks beyond the antibiotic
treatment, Surawicz et al. (1990) reported AAD in 9.5% of the
probiotic-treated group versus 21.8% (P < 0.05) in the placebo
group. In a study (involving 151 patients) of the preventive effect
of S. boulardii given only for the duration of the antibiotic treat-
ment,Can et al. (2006) found AAD in 1.4% of the probiotic-treated
group versus 9.0% in the placebo group. Similar results have been
obtained by Cremonini et al. (2002) and Duman et al. (2005).
Clostridium difficile associated diarrhea. The effects of S.
boulardii on C. difficile have also been studied. C. difficile is
responsible for 20% of antibiotic associated diarrhea cases (Kelly
et al., 1994; Krämer and Bischoff, 2006) and causes pseudomem-
branous colitis, an infection of the colon. There are only two
standard antibiotics for C. difficile infection, namely vancomycin
and metronidazole, and the response rate to the later has been
declining (McFarland, 2007). S. boulardii in combination with
antibiotics has been shown effective for treating C. difficile associ-
ated diarrhea and colitis (Mcfarland et al., 1994; McFarland, 2010;
Surawicz et al., 2000). In a randomized placebo-controlled trial
of 124 patients suffering from C. difficile infection (Mcfarland
et al., 1994), standard antibiotics were combined with S. boulardii
(500 mg/day) or placebo. Patient follow-up revealed a significant
reduction in C. difficile infection reoccurrence in those treated with
S. boulardii (34.6% compared to 64.7% for the placebo, P = 0.04).
In a similar study involving 170 patients (Surawicz et al., 2000),
reoccurrence in the S. boulardii-treated group was 16.7% com-
pared to 50% for the placebo group (P = 0.05). In a more recent
comparison of the efficacy of a mixture of probiotics, McFarland
et al. (2006) concluded that only S. boulardii was effective against
C. difficile infection.
The effects of S. boulardii have also been studied in vitro and
in animal models such as gnotobiotic mice (Elmer and Corthier,
1991; Elmer et al., 1999; Castex et al., 1990) rats (Karen et al., 2010;
Sezer et al., 2009), and turkeys (Bradley et al., 1994). Czerucka and
Rampal (2002) linked the effects of S. boulardii to the produc-
tion of a 54-KDa protease. Its mechanism appears to degrade C.
difficile toxins (Castagliuolo et al., 1996; Qamar et al., 2001), and
could do likewise to the colonic cell surface receptors for C. diffi-
cile (Pothoulakis et al., 1993; Castagliuolo et al., 1996; Pothoulakis,
2009; Castagliuolo et al., 1999), or otherwise inhibit C. difficile
attachment to intestinal cells (Buts and Bernasconi, 2005; Buts,
2009; Tasteyre et al., 2002). S. boulardii also appears to increase
the immune response to C. difficile toxins A and B (Buts, 2009). It
has been demonstrated that S. boulardii stimulates an increase in
intestinal immunoglobin A secretion during a C. difficile toxin A
challenge in mice (Qamar et al., 2001; Figure 1).
Traveler’s diarrhea. Each year million of people worldwide
develop traveler’s diarrhea. S. boulardii activities in the prevention
of traveler’s diarrhea have been widely investigated. In 1016 travel-
ers visiting various countries in the world Kollaritsch et al. (1993)
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reported a significant reduction in diarrhea among patients receiv-
ing 5 billion CFU of S. boulardii/day (34% versus 40% in patients
receiving placebo P = 0.019). Based on analysis of 12 studies of the
use of probiotics to prevent traveler’s diarrhea, McFarland (2007)
reported a significant benefit of two probiotics, namely S. boulardii
and a mixture of Lactobacillus acidophilus and Bifidobacterium
bifidum.
Acute diarrhea in adults and children. Every year, an estimated
2 million deaths worldwide occur as a result of acute diarrhea
(Billoo et al., 2006). Several studies have shown the beneficial
effects of S. boulardii in preventing acute diarrhea. In a group
of 50 children (aged 2 months to 2 years) receiving 10 billion CFU
of S. boulardii/day or a placebo in combination with oral rehy-
dration salt and nutritional support, Billoo et al. (2006) showed
significant reductions in stool frequency and duration of diarrhea
in the S. boulardii group compared to the placebo group. In a
double-blind randomized study, Kurugöl and Koturoglu (2005)
noted a significant reduction in the number of days with diarrhea
and hospitalization among 200 children treated with S. boulardii.
Similar results were found in another double-blind randomized
study by Villarruel et al. (2007).
Tube-feeding-associated diarrhea. DeMeo et al. (1998) esti-
mated that approximately 68% of tube-fed patients develop diar-
rhea. Several studies suggest the beneficial effects of S. boulardii
in restoring normal intestinal microflora and preventing tube-
feeding-associated diarrhea. In a double-blind placebo-controlled
trial involving 40 tube-fed patients, a 50% reduction in days
with diarrhea was observed among patients given S. boulardii
compared to the placebo group (Tempé et al., 1983). Another
double-blind placebo-controlled study following 128 critically ill
tube-fed patients (Bleichner et al., 1997) showed a significant
but small reduction in days with diarrhea among patients given
40 billion CFU of S. boulardii four times/day (14.2 versus 18.9%
in patients receiving placebo).
Inflammatory bowel disorders. Inflammatory bowel diseases
(IBD), Crohn’s disease, ulcerative colitis and Irritable bowel syn-
drome are chronic inflammatory disorders of the gastrointestinal
tract. Numerous studies showed that S. boulardii hold promise
for the treatment of inflammatory bowel disorders. In a double-
blind study of 20 patients suffering from Crohn’s disease (Plein and
Hotz, 1993) showed a significant reduction in the bowel movement
among patients receiving S. boulardii in addition to their conven-
tional therapy. In a single-blind study of 32 patients with Crohn’s
disease (Guslandi et al., 2000), similar results were reported for
patients receiving S. boulardii (20× 109 CFU/day) compared to
patients receiving 500 mg of mesalazine three times daily. Gus-
landi et al. (2003) reported improvement of 68% of patients with
ulcerative colitis receiving mesalazine (3 g/day) and 250 mg of
S. boulardii in capsules three times daily for 4 weeks. Finally, S.
boulardii has been shown to exert promising beneficial effect in
the treatment of IBD. One suggested mechanism unique action
on inflammation by specific alteration of the migratory behavior
of T cells, which accumulate in mesenteric lymph nodes (Dal-
masso et al., 2006a,b). S. boulardii treatment might thus limit the
infiltration of T-helper 1 cells, and hence colonic inflammation
and amplification thereof by pro-inflammatory cytokines.
Further in vivo studies are required to investigate the ability
of various yeasts strain to exercise their probiotic effect (Foligné
et al., 2010). Also, further studies are requiring an optimal and con-
trolled probiotic formula to enhance the biotherapeutic effects of
yeast.
Chronic diarrhea in human immunodeficiency virus and oth-
ers. In a randomized double-blind study of 35 patients with
AIDS-related diarrhea, Saint-Marc et al. (1995) reported a reduc-
tion in diarrhea among patients receiving S. boulardii (3 g/day for
7 days). After 1 week of treatment with S. boulardii, 61% of the
patients were diarrhea-free compared with 12% in the placebo
group. Finally, other studies revealed the efficacy of S. boulardii to
reduce diarrhea in people suffering from giardiasis (Besirbellioglu
et al., 2006), amebiasis (Mansour-Ghanaei et al., 2003; Tanyuksel
and Petri, 2003) where S. boulardii reduces the number of red cells
adhering to amoeba and the number of amoebae bearing red cells
(Rigothier et al., 1994), and Helicobacter pylori gastritis (Duman
et al., 2005). It was reported that S. boulardii had improved the
post-treatment dyspepsia symptoms of H. pyloris infection with-
out having a significant effect on the rate of H. pylori eradication
(Cindoruk et al., 2007). Recently, Vandenplas et al. (2009) sug-
gested that S. boulardii alters the structure of H. pylori. Further
studies are required for better understanding of yeast probiotics
mechanisms.
Probiotic bacteria/yeast interaction. Because probiotic yeast and
bacteria have different mechanisms of action, a synergetic effect
and higher viability might be expected from mixing both types
of probiotics (Bisson et al., 2010 and Suharja et al., 2012). Several
studies showed that yeasts could positively interact with probiotic
bacterial by enhancing their survival and stimulating their growth
(Gobbetti et al., 1994; Liu and Tsao, 2009a,b,c; Katakura et al., 2010;
Suharja et al., 2012). This positive interaction between yeast and
bacteria might be attributed to the production of nutrients such
as peptides, amino acids, and/or vitamins (Gobbetti et al., 1994;
Viljoen, 2001, 2006; Narvhus and Gadaga, 2003; Kawarai et al.,
2007; Katakura et al., 2010). It is well known that the cell wall of
yeasts is mainly composed of glucans, mannans, and chitin, all of
which may play a role in co-aggregation and cohesion phenomena
which play a major role in the survival of probiotic bacteria (Chaf-
fin et al., 1998; Millsap et al., 1998). Aggregation may involve the
yeast mannans form a capsule-like structure where bacteria may
associate with sugars by means of a lectin-like (Millsap et al., 1998).
Katakura et al. (2010) identified proteins on the surface of Lacto-
coccus lactis IL1403, which recognize the yeast mannan involved
in adhesion of lactic acid bacterium to the yeast. Also, in the study
of interactions between microorganisms present in kefir grains,
Golowczyc et al. (2009) showed that thermolabile non-covalently
lectin-like surface proteins of several Lactobacillus kefir strains can
mediate the aggregation with S. liplytica CIDCA 812 yeast cells.
It has been hypothesized by Xie et al. (2012) that the aggregation
of LAB with yeasts in gastric or intestinal juices might have pos-
itive effects on enhancing the tolerance of LAB. The same group
concluded that proteins of the cell surface of Labacillus paracasei
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H9 and polysaccharides in cell walls of S. cerevisiae play impor-
tant roles in co-aggregation of the two strains and the microbial
adhesion specificity to Caco-2 cells that contributes to enhanc-
ing probiotic potentials of L. paracasei H9. Also, Liu and Tsao
(2010a,b) reported that the use of Williopsis saturnus var. saturnus
enhances the survival of the two probiotic bacteria L. bulgaricus
and L. rhamnosus in fermented milk. The same group concluded
that the use of yeast enhance the stability of probiotic bacteria in
fermented milk thereby extend the product shelf-life and retain
nutritional value (Liu and Tsao, 2010a,b).
Other medical application
The relatively recent discovery of bio-drug effects of yeasts poten-
tially opens a door to new clinical applications. Blanquet et al.
(2001) defined bio-drugs as orally administered living recombi-
nant microorganisms that express disease-fighting proteins. The
application of non-recombinant yeast as antimycotics for thera-
peutic treatment of human and animal fungal infection has also
received considerable attention (Polonelli et al., 1986; Hodgson
et al., 1995; Séguy et al., 1998; Conti et al., 2002; Schmitt and
Breinig, 2002). The killer toxin of L. mrakii has been proposed
as an antifungal compound against Candida spp., due to its sim-
ilarity to aculeacin and stability to pH and temperature changes
(Walker et al., 1995; Hodgson et al., 1995). Weiler and Schmitt
(2003) found that the zygocin, produced by Zygosaccharomyces
bailii, has a rapid killing effect against a wide range of pathogenic
yeasts including Candida albicans, Candida glabrata and Candida
krusei, and Sporothrix schenckii based on disruption of membrane
ion gradients. However, it is important to note that killer toxins
are large glycoprotein compounds and hence capable of induc-
ing an immune response in the host. To deal with this potential
challenge, several strategies have been proposed. For example,
Magliani et al. (1997) synthesized small non-antigenic peptides
with killer activity. The same group suggested the utilization of an
anti-idiotypic antibodies from killer toxin secreted by W. anomalus
(Magliani et al., 2008). These “antibiobodies” (i.e., immunoglobu-
lin molecules acting directly to provide passive immunity without
involvement of other immune system factors) showed a signifi-
cant microbicidal activity against wide range of pathogenic agents
through the interaction with specific killer toxin receptors com-
posed by beta-glucans. A novel antifungal vaccine derivative of
W. anomalus killer toxin (PaKT) has been described recently by
Polonelli et al. (2011).
VETERINARY APPLICATIONS
Yeast as a source of protein, vitamins, and minerals in animal feeds
and for veterinary use has a long history (Anupama and Ravindra,
2000; Bekatorou et al., 2006). Yeast single cell protein is effective
for accelerating growth and improving the well-being of cattle
by stimulating rumen acetogens (Halász and Lásztity, 1991; Klein
and Favreau, 1995; Kurtzman et al., 2011a,b). The use of yeast cell
wall polysaccharides as adjuncts for animal and fish feeds has been
found to improve the health of growing pigs (Sauerwein et al.,
2007). Increasing resistance of bacterial pathogens to antibiotics,
due largely to overuse of these compounds in livestock production,
has fueled the search for alternative strategies such as probiotics
to ensure animal health (Dawson et al., 1990; Li et al., 2006; van
Heugten et al., 2003). S. cerevisiae was has been used in many
probiotic preparations (Lyons et al., 1993; Edens, 2003; Swanson
et al., 2002a,b). Yeast may act by various mechanisms such as mod-
ulation of immune system, histamine release (Holck et al., 2007),
binding to toxins, and to pathogenic cell (Castex et al., 1990; Elmer
and Corthier, 1991; Elmer and McFarland, 1987), interactions with
gut constituents, and anti-tumor activities (Ghoneum et al., 2007).
Several studies of poultry have shown that S. boulardii increases
bird weight when used as a feed supplement during the early
stages of life (Bradley et al., 1994; Hooge, 2004; Gao et al., 2008;
Patterson and Burkholder, 2003). Investigating the effect of 1–
100 g of dried S. boulardii/kg of feed, Line et al. (1998) found that
colonization of the cecum of broiler chickens challenged with Sal-
monella typhimurium (3.2× 108 CFU) was 5–20% and inversely
proportional to the amount of yeast given, compared to 70% in
birds not fed the yeast. Investigating the impact of viable cells
(6.5× 1010 CFU/kg of feed), extract, or cell wall of S. cerevisiae
on growth, meat quality, and ileal mucosal development in male
broiler chickens, Zhang et al. (2005) concluded that whole yeast
improved growth rate as well as meat tenderness and oxidative
stability, while cell wall improved ileal mucosal development only.
Other authors have obtained similar results with broiler chickens
and other animals (Lammerding et al., 1988; Morales-López et al.,
2010).
Positive results have also been obtained in ruminants. Until
recently, the most consistent beneficial effect of feeding S. cere-
visiae to ruminant has been stabilization of the rumen pH or
prevention of acidosis caused by rapid fermentation of large quan-
tities of carbohydrates (Chiquette, 2009). It has been demonstrated
in vitro that S. cerevisiae can stimulate the digestion of cellulose
by cellulolytics organisms such as Fibrobacter succinogenes and
Ruminococcus flavefaciens and promotes the utilization of lactate
by Megasphaera elsdenii and Selenomonas ruminantium (Call-
away and Martin, 1997). It is also well known that feeding yeast
stimulates rumen microbial growth and oxygen scavenging, thus
creating more favorable conditions for anaerobic microorganisms
(Fonty and Chaucheyras-Durand, 2006). Finally, the mode of
action of probiotic yeast in the rumen depends on several fac-
tors such as yeast strain, viability, and the composition of the diet
of the animal (Chiquette, 2009).
The applications of yeasts in human foods and animal feeds as
well as in agriculture and other sectors are increasing and mar-
ket demand is providing motivation to continue or even increase
research and development in this field. Only future studies will
reveal the ultimate potential of these microorganisms in different
fields of application.
ACKNOWLEDGMENTS
Support for this research was received in the form of grants from
the Fonds de recherche sur la nature et les technologies Québec
(FQRNT), the Ministère de l’Agriculture, des Pêcheries et de
l’Alimentation du Québec (MAPAQ), Novalait, and Agriculture
and Agri-Food Canada (AAC). The authors thank Dr. Stephen
Davids for critical reading of the manuscript and Riadh Hammami
for the technical support.
www.frontiersin.org December 2012 | Volume 3 | Article 421 | 7
Hatoum et al. Antimicrobial properties of yeast
REFERENCES
Adam, J., Barret, A., and Barret-Bellet,
C. (1976). Essai clinique controle
en double issu de l’ultra levure
lyophilisee. Med. Chir. Digest. 5,
401–406.
Alexandre, H., Costello, P. J., Rem-
ize, F., Guzzo, J., and Guilloux-
Benatier, M. (2004). Saccharomyces
cerevisiae – Oenococcus oeni inter-
actions in wine: current knowledge
and perspectives. Int. J. Food Micro-
biol. 93, 141–154.
Almeida,M. J., and Pais,C. (1996). Leav-
ening ability and freeze tolerance of
yeasts isolated from traditional corn
and rye bread doughs. Appl. Environ.
Microbiol. 62, 4401–4404.
Anupama, X., and Ravindra, P. (2000).
Value-added food: single cell pro-
tein. Biotechnol. Adv. 18, 459–479.
Asehraou, A., Peres, C., Brito, D., Faid,
M., and Serhrouchni, M. (2007).
Characterization of yeast strains iso-
lated from bloaters of fermented
green table olives during storage.
Grasas Aceites 51, 225–229.
Bekatorou, A., Psarianos, C., and Kouti-
nas, A. A. (2006). Production of
food grade yeasts. Biopolymers 44,
407–415.
Besirbellioglu, B. A., Ulcay, A., Can, M.,
Erdem, H., Tanyuksel, M., Avci, I. Y.,
et al. (2006). Saccharomyces boulardii
and infection due to Giardia lamblia.
Scand. J. Infect. Dis. 38, 479–481.
Bevan, E. A., and Somers, J. M. (1969).
Somatic segregation of the killer (k)
and neutral (n) cytoplasmic genetic
determinants in yeast. Genet. Res. 14,
71–77.
Bilinski, C. A., and Casey, G. P. (1989).
Developments in sporulation and
breeding of brewer’s yeast. Yeast 5,
429–438.
Billoo, A. G., Memon, M. A., Khaskheli,
S. A., Murtaza, G., Iqbal, K., Saeed
Shekhani, M., et al. (2006). Role of a
probiotic (Saccharomyces boulardii)
in management and prevention of
diarrhoea. World J. Gastroenterol. 12,
4557–4560.
Bisson, J.-F., Hidalgo, S., Rozan, P., and
Messaoudi, M. (2010). Preventive
effects of different probiotic formu-
lations on travelers’ diarrhea model
in wistar rats: preventive effects of
probiotics on TD. Dig. Dis. Sci. 55,
911–919.
Blanquet, S., Marol-Bonnin, S., Beyssac,
E., Pompon, D., Renaud, M., and
Alric, M. (2001). The biodrug
concept: an innovation approach
to therapy. Trends Biotechnol. 19,
393–400.
Bleichner, G., Bléhaut, H., Mentec,
H., and Moyse, D. (1997). Saccha-
romyces boulardii prevents diarrhea
in critically ill tube-fed patients.
Intensive Care Med. 23, 517–523.
Boone, C., Sdicu, A., Degri, R., Sanchez,
C., and Bussey, H. (1990). Integra-
tion of the yeast “KI” killer toxin
in gene into the genome of marked
wine yeasts and its effect on vinifica-
tion. Yeast 41, 37–42.
Bortol, A., Nudel, C., Fraile, E., Tor-
res, R., Giulietti, A., Spencer, J. F.
T., et al. (1986). Isolation of yeast
with killer activity and its breeding
with an industrial baking strain by
protoplast fusion. Appl. Microbiol.
Biotechnol. 24, 414–416.
Bradley, G. L., Savage, T. F., and
Timm, K. I. (1994). The effects
of supplementing diets with Sac-
charomyces cerevisiae var. boulardii
on male poult performance and
ileal morphology. Poult. Sci. 73,
1766–1770.
Bravo, M. V., Bunout, D., Leiva, L., De La
Maza, M. P., Barrera, G., De La Maza,
J., et al. (2008). Effect of probiotic
Saccharomyces boulardii on preven-
tion of antibiotic-associated diar-
rhea in adult outpatients with amox-
icillin treatment. Rev. Med. Chil. 136,
981–988.
Buts, J.-P. (2009). Twenty-five years of
research on Saccharomyces boulardii
trophic effects: updates and perspec-
tives. Dig. Dis. Sci. 54, 15–18.
Buts, J.-P., and Bernasconi, P. (2005).
Saccharomyces boulardii: basic sci-
ence and clinical applications in gas-
troenterology. Gastroenterol. Clin.
North Am. 34, 515–532.
Callaway, E. S., and Martin, S. A. (1997).
Effects of a Saccharomyces cerevisiae
culture on ruminal bacteria that uti-
lize lactate and digest cellulose. J.
Dairy Sci. 80, 2035–2044.
Can, M., Besirbellioglu, B. A., Avci,
I. Y., Beker, C. M., and Pahsa,
A. (2006). Prophylactic Saccha-
romyces boulardii in the prevention
of antibiotic-associated diarrhea: a
prospective study. Med. Sci. Monit.
12, PI19–PI22.
Castagliuolo, I., LaMont, J. T., Niku-
lasson, S. T., and Pothoulakis, C.
(1996). Saccharomyces boulardii pro-
tease inhibits Clostridium difficile
toxin A effects in the rat ileum. Infect.
Immun. 64, 5225–5232.
Castagliuolo, I., Riegler, M. F., Valenick,
L., LaMont, J. T., and Pothoulakis, C.
(1999). Saccharomyces boulardii pro-
tease inhibits the effects of Clostrid-
ium difficile toxins A and B in human
colonic mucosa. Infect. Immun. 67,
302–307.
Castex, F., Corthier, G., Jouvert, S.,
Elmer, G. W., Lucas, F., and Bastide,
M. (1990). Prevention of Clostrid-
ium difficile-induced experimental
pseudomembranous colitis by Sac-
charomyces boulardii: a scanning
electron microscopic and microbio-
logical study. J. Gen. Microbiol. 136,
1085–1089.
Cavalero, D. A., and Cooper, D. G.
(2003). The effect of medium com-
position on the structure and phys-
ical state of sophorolipids produced
by Candida bombicola ATCC 22214.
J. Biotechnol. 103, 31–41.
Chaffin, W. L., López-Ribot, J. L.,
Casanova, M., Gozalbo, D., and
Martínez, J. P. (1998). Cell wall and
secreted proteins of Candida albi-
cans: identification, function, and
expression. Microbiol. Mol. Biol. Rev.
62, 130–180.
Chen, L.-S., Ma, Y., Maubois, J.-L., He,
S.-H., Chen, L.-J., and Li, H.-M.
(2010). Screening for the potential
probiotic yeast strains from raw milk
to assimilate cholesterol. Dairy Sci.
Technol. 90, 537–548.
Chen, W.-B., Han, Y.-F., Jong, S.-C.,
and Chang, S.-C. (2000). Isola-
tion, purification, and characteriza-
tion of a killer protein from Schwan-
niomyces occidentalis. Appl. Environ.
Microbiol. 66, 1029–1035.
Chiquette, J. (2009). Evaluation of the
protective effect of probiotics fed to
dairy cows during a subacute rumi-
nal acidosis challenge. Anim. Feed
Sci. Technol. 153, 278–291.
Ciani, M., and Fatichenti, F. (2001).
Killer toxin of Kluyveromyces phaf-
fii DBVPG 6076 as a biopreserva-
tive agent to control apiculate wine
yeasts. Appl. Environ. Microbiol. 67,
3058–3063.
Cindoruk, M., Erkan, G., Karakan, T.,
Dursun, A., and Unal, S. (2007).
Efficacy and safety of Saccha-
romyces boulardii in the 14-day triple
anti-Helicobacter pylori therapy: a
prospective randomized placebo-
controlled double-blind study. Heli-
cobacter 12, 309–316.
Comitini, F., De Ingeniis, J., Pepe,
L., Mannazzu, I., and Ciani,
M. (2004a). Pichia anomala
and Kluyveromyces wickerhamii
killer toxins as new tools against
Dekkera/Brettanomyces spoilage
yeasts. FEMS Microbiol. Lett. 238,
235–240.
Comitini, F., Di Pietro, N., Zacchi, L.,
Mannazzu, I., and Ciani, M. (2004b).
Kluyveromyces phaffii killer toxin
active against wine spoilage yeasts:
purification and characterization.
Microbiology 150, 2535–2541.
Conti, S., Magliani,W.,Arseni, S., Frazzi,
R., Salati, A., Ravanetti, L., et al.
(2002). Inhibition by yeast killer
toxin-like antibodies of oral Strep-
tococci adhesion to tooth surfaces
in an ex vivo model. Mol. Med. 8,
313–317.
Coté, G. A., and Buchman, A. L.
(2006). Antibiotic-associated diar-
rhoea. Expert Opin. Drug. Saf. 5,
361–372.
Cremonini, F., Di Caro, S., Covino, M.,
Armuzzi, A., Gabrielli, M., Santarelli,
L., et al. (2002). Effect of differ-
ent probiotic preparations on anti-
Helicobacter pylori therapy-related
side effects: a parallel group, triple
blind, placebo-controlled study. Am.
J. Gastroenterol. 97, 2744–2749.
Czerucka, D., Piche, T., and Ram-
pal, P. (2007). Review article:
yeast as probiotics – Saccharomyces
boulardii. Aliment. Pharmacol. Ther.
26, 767–778.
Czerucka, D., and Rampal, P. (2002).
Experimental effects of Saccha-
romyces boulardii on diarrheal
pathogens. Microbes Infect. 4,
733–739.
Dalmasso, G., Cottrez, F., Imbert, V.,
Lagadec, P., Peyron, J.-F., Ram-
pal, P., et al. (2006a). Saccha-
romyces boulardii inhibits inflam-
matory bowel disease by trapping
T cells in mesenteric lymph nodes.
Gastroenterology 131, 1812–1825.
Dalmasso, G., Loubat, A., Dahan, S.,
Calle, G., Rampal, P., and Czerucka,
D. (2006b). Saccharomyces boulardii
prevents TNF-alpha-induced apop-
tosis in EHEC-infected T84 cells.
Res. Microbiol. 157, 456–465.
Dawes, E. A. (1986). Microbial energet-
ics. Biochem. Educ. 95, 187.
Dawson, K. A., Newman, K. E., and Bol-
ing, J. A. (1990). Effects of microbial
supplements containing yeast and
lactobacilli on roughage-fed ruminal
microbial activities. J. Anim. Sci. 68,
3392–3398.
Deak, T. (2006). “Environmental factors
influencing yeasts,” in Biodiversity
and Ecophysiology of Yeasts (The Yeast
Handbook series), eds G. Péter and C.
Rosa (Berlin: Springer), 155–174.
DeMeo, M., Kolli, S., Keshavarzian, A.,
Borton, M., Al-Hosni, M., Dyavana-
palli, M., et al. (1998). Beneficial
effect of a bile acid resin binder
on enteral feeding induced diarrhea.
Am. J. Gastroenterol. 93, 967–971.
Dickinson, J., and Kruckeberg, A.
(2006). “Carbohydrate metabolism,”
in Yeasts in Food and Beverages,
eds A. Querol and G. Fleet (Berlin:
Springer), 215–242.
Dieuleveux, V., Van Der Pyl, D.,
Chataud, J., and Gueguen, M.
(1998). Purification and charac-
terization of anti-Listeria com-
pounds produced by Geotrichum
candidum. Appl. Environ. Microbiol.
64, 800–803.
Frontiers in Microbiology | Food Microbiology December 2012 | Volume 3 | Article 421 | 8
Hatoum et al. Antimicrobial properties of yeast
D’Souza, A. L., Rajkumar, C., Cooke, J.,
and Bulpitt, C. J. (2002). Probiotics
in prevention of antibiotic associ-
ated diarrhoea: meta-analysis. BMJ
324, 1361.
Duman, D. G., Bor, S., Ozütemiz, O.,
Sahin, T., Oguz, D., Istan, F., et al.
(2005). Efficacy and safety of Saccha-
romyces boulardii in prevention of
antibiotic-associated diarrhoea due
to Helicobacter pylori eradication.
Eur. J. Gastroenterol. Hepatol. 17,
1357–1361.
Edens, F. W. (2003). An alternative for
antibiotic se in poultry: probiotics.
Rev. Bras. Cienc. Avic. 5, 75–97.
Elmer, G. W., and Corthier, G. (1991).
Modulation of Clostridium difficile
induced mortality as a function of
the dose and the viability of the Sac-
charomyces boulardii used as a pre-
ventative agent in gnotobiotic mice.
Can. J. Microbiol. 37, 315–317.
Elmer, G. W., and McFarland, L. V.
(1987). Suppression by Saccha-
romyces boulardii of toxigenic
Clostridium difficile overgrowth
after vancomycin treatment in ham-
sters. Antimicrob. Agents Chemother.
31, 129–131.
Elmer, G. W., McFarland, L. V., Suraw-
icz, C. M., Danko, L., and Green-
berg, R. N. (1999). Behaviour of
Saccharomyces boulardii in recur-
rent Clostridium difficile disease
patients. Aliment. Pharmacol. Ther.
13, 1663–1668.
El-neshawy, S. M., and Wilson, C.
L. (1997). Nisin enhancement of
biocontrol of postharvest diseases
of apple with Candida oleophila.
Postharvest Biol. Technol. 10, 9–14.
Erdeve, O., Tiras, U., and Dallar, Y.
(2004). The probiotic effect of Sac-
charomyces boulardii in a pediatric
age group. J. Trop. Pediatr. 50,
234–238.
Etienne-Mesmin, L., Livrelli, V., Privat,
M., Denis, S., Cardot, J.-M., Alric,
M., et al. (2011). Effect of a new
probiotic Saccharomyces cerevisiae
strain on survival of Escherichia coli
O157:H7 in a dynamic gastrointesti-
nal model. Appl. Environ. Microbiol.
77, 1127–1131.
Fatichenti, F., Bergere, J. L., Deiana, P.,
and Farris, G. A. (1983). Antagonis-
tic activity of Debaryomyces hansenii
towards Clostridium tyrobutyricum
and C. butyricum. J. Dairy Res. 50,
449–457.
Fleet, G. H. (2007). Yeasts in foods and
beverages: impact on product qual-
ity and safety. Curr. Opin. Biotechnol.
18, 170–175.
Foligné, B., Dewulf, J., Vandekerckove,
P., Pignède, G., and Pot, B. (2010).
Probiotic yeasts: anti-inflammatory
potential of various non-pathogenic
strains in experimental colitis in
mice. World J. Gastroenterol. 16,
2134–2145.
Fonty, G., and Chaucheyras-Durand, F.
(2006). Effects and modes of action
of live yeasts in the rumen. Biologia
61, 741–750.
Fredlund, E., Blank, L. M., Schnürer,
J., Sauer, U., and Passoth, V. (2004).
Oxygen- and glucose-dependent
regulation of central carbon metab-
olism in Pichia anomala. Appl. Envi-
ron. Microbiol. 70, 5905–5911.
Gao, J., Zhang, H. J., Yu, S. H.,
Wu, S. G., Yoon, I., Quigley, J.,
et al. (2008). Effects of yeast cul-
ture in broiler diets on performance
and immunomodulatory functions.
Poult. Sci. 87, 1377–1384.
Ghoneum, M., Wang, L., Agrawal, S.,
and Gollapudi, S. (2007). Yeast ther-
apy for the treatment of breast can-
cer: a nude mice model study. In vivo
21, 251–258.
Gobbetti, M., Corsetti, A., and Rossi, J.
(1994). The sourdough microflora.
Interactions between lactic acid bac-
teria and yeasts: metabolism of car-
bohydrates. Appl. Microbiol. Biotech-
nol. 41, 456–460.
Goerges, S., Aigner, U., Silakowski, B.,
and Scherer, S. (2006). Inhibition
of Listeria monocytogenes by food-
borne yeasts. Appl. Environ. Micro-
biol. 72, 313–318.
Goerges, S., Koslowsky, M., Velagic, S.,
Borst, N., Bockelmann, W., Heller,
K. J., et al. (2011). Anti-listerial
potential of food-borne yeasts in
red smear cheese. Int. Dairy J. 21,
83–89.
Goldman, E. (2008). Practical
Handbook of Microbiology, 2nd
Edn, eds. E. Goldman and L.
Green (CRC Press). Available at:
http://www.crcnetbase.com/doi/
book/10.1201/9781420009330.
Golowczyc, M. A., Mobili, P., Gar-
rote, G. L., de los Angeles Ser-
radell, M., Abraham, A. G., and
De Antoni, G. L. (2009). Inter-
action between Lactobacillus kefir
and Saccharomyces lipolytica iso-
lated from kefir grains: evidence
for lectin-like activity of bacterial
surface proteins. J. Dairy Res. 76,
111–116.
Golubev, W. I. (2006). “Antagonistic
interactions among yeasts,” in Bio-
diversity and Ecophysiology of Yeasts,
eds. G. Péter and C. Rosa (Berlin:
Springer), 197–219.
Gunge, N., Tamaru, A., Ozawa, F.,
and Sakaguchi, K. (1981). Isola-
tion and characterization of lin-
ear deoxyribonucleic acid plasmids
from Kluyveromyces lactis and the
plasmid- associated killer character.
Yeast 145, 382–390.
Guslandi, M., Giollo, P., and Testoni, P.
A. (2003). A pilot trial of Saccha-
romyces boulardii in ulcerative coli-
tis. Eur. J. Gastroenterol. Hepatol. 15,
697–698.
Guslandi, M., Mezzi, G., Sorghi, M., and
Testoni, P. A. (2000). Saccharomyces
boulardii in maintenance treatment
of Crohn’s disease. Dig. Dis. Sci. 45,
1462–1464.
Halász, A., and Lásztity, R. (1991). Use
of Yeast Biomass in Food Produc-
tion. CRC Press, 352. Available at:
http://books.google.ca/books?id=
xbZRt2pKwqUC
Hara, S., Iimura, Y., and Otsuka, K.
(1980). Breeding of useful killer
wine yeasts. Am. J. Enol. Vitic. 31,
28–33.
Hatoum, R., Labrie, S., and Fliss, I.
(2012). Identification and partial
characterization of antilisterial com-
pounds produced by dairy yeasts.
Probiotics Antimicrob. Proteins 1–10.
doi: 10.1007/s12602-012-9109-8
Hayduck, F. (1909). Uber einen
Hefengiftstoff in Hefe. Wochenschr.
Brau. 26, 677–679.
Hayman, G. T., and Bolen, P. L. (1991).
Linear DNA plasmids of Pichia inos-
itovora are associated with a novel
killer toxin activity. Curr. Genet. 19,
389–393.
Hernández, A., Martín, A., Córdoba, M.
G., Benito, M. J., Aranda, E., and
Pérez-Nevado, F. (2008). Determi-
nation of killer activity in yeasts iso-
lated from the elaboration of sea-
soned green table olives. Int. J. Food
Microbiol. 121, 178–188.
Hibbett, D. S., Binder, M., Bischoff, J. F.,
Blackwell, M., Cannon, P. F., Eriks-
son, O. E., et al. (2007). A higher-
level phylogenetic classification of
the Fungi. Mycol. Res. 111, 509–547.
Hodgson, V. J., Button, D., and Walker,
G. M. (1995). Anti-candida activity
of a novel killer toxin from the yeast
Williopsis mrakii. Microbiology 141,
2003–2012.
Holck, P., Sletmoen, M., Stokke, B. T.,
Permin, H., and Norn, S. (2007).
Potentiation of histamine release by
Microfungal (1→3)- and (1→6)-
beta-d-glucans. Basic Clin. Pharma-
col. Toxicol. 101, 455–458.
Hooge, D. M. (2004). Meta-analysis
of broiler chicken pen trials evalu-
ating dietary mannan oligosaccha-
ride, 1993–2003. Int. J. Poult. Sci. 3,
163–174.
Htwe, K., Yee, K. S., Tin, M., and Van-
denplas, Y. (2008). Effect of Saccha-
romyces boulardii in the treatment of
acute watery diarrhea in myanmar
children: a randomized controlled
study. Am. J. Trop. Med. Hyg. 78,
214–216.
Ibeas, J. I., Lozano, I., Perdigones,
L., and Jimenez, J. (1996). Detec-
tion of Dekkera/Brettanomyces
strains in sherry by a nested PCR
method. Appl. Environ. Microbiol.
62, 998–1003.
Izgu, F., and Altinbay, D. (2004).
Isolation and characterization of
the K5-type yeast killer protein
and its homology with an exo-
beta-1,3-glucanase. Biosci. Biotech-
nol. Biochem. 68, 685–693.
Izgu, F., Altinbay, D., and Acun, T.
(2006). Killer toxin of Pichia anom-
ala NCYC 432; purification, char-
acterization and its exo-beta-1,3-
glucanase activity. Enzyme Microb.
Technol. 39, 669–676.
Jakobsen, M., and Narvhus, J. (1996).
Yeasts and their possible beneficial
and negative effects on the quality
of dairy products. Int. Dairy J. 6,
755–768.
Kagan, B. L. (1983). Mode of action
of yeast killer toxins: channel
formation in lipid bilayer mem-
branes. Nature 302, 709–711.
Karen, M., Yuksel, O., Akyürek, N.,
Ofluoglu, E., Caglar, K., Sahin, T.
T., et al. (2010). Probiotic agent
Saccharomyces boulardii reduces
the incidence of lung injury in
acute necrotizing pancreatitis
induced rats. J. Surg. Res. 160,
139–144.
Katakura, Y., Sano, R., Hashimoto,
T., Ninomiya, K., and Shioya, S.
(2010). Lactic acid bacteria dis-
play on the cell surface cytosolic
proteins that recognize yeast man-
nan. Appl. Microbiol. Biotechnol. 86,
319–326.
Kawarai, T., Furukawa, S., Ogihara, H.,
and Yamasaki, M. (2007). Mixed-
species biofilm formation by lac-
tic acid bacteria and rice wine
yeasts. Appl. Environ. Microbiol. 73,
4673–4676.
Kelly, C. P., Pothoulakis, C., and LaM-
ont, J. T. (1994). Current concepts:
Clostridium difficile colitis. N. Engl.
J. Med. 330, 257–262.
Kimura, T., Kitamoto, N., Matsuoka, K.,
Nakamura, K., Iimura, Y., and Kito,
Y. (1993). Isolation and nucleotide
sequences of the genes encod-
ing killer toxins from Hansenula
mrakii and H. saturnus. Gene 137,
265–270.
Kitamoto, H. K., Hasebe, A., Ohmomo,
S., Suto, E. G., Muraki, M., and
Iimura, Y. (1999). Prevention of
aerobic spoilage of maize silage
by a genetically modified killer
yeast, Kluyveromyces lactis, defec-
tive in the ability to grow on lactic
www.frontiersin.org December 2012 | Volume 3 | Article 421 | 9
Hatoum et al. Antimicrobial properties of yeast
acid. Appl. Environ. Microbiol. 65,
4697–4700.
Klein, R. D., and Favreau, M. A. (1995).
“The Candida species: biochemistry,
molecular biology, and industrial
applications,”in Food Biothechnology
Microorganisms, eds Y. H. Hui and G.
G. Khachatourians (New York: VCH
publishers), 297–371.
Kollaritsch, H., Holst, H., Grobara, P.,
and Wiedermann, G. (1993). Pre-
vention of traveler’s diarrhea with
Saccharomyces boulardii. Results
of a placebo controlled double-
blind study. Fortschr. Med. 111,
153–156.
Kono, I., and Himeno, K. (1997).
A novel killer yeast effective on
Schizosaccharomyces pombe.
Biosci. Biotechnol. Biochem. 61,
563–564.
Kotowska, M., Albrecht, P., and Sza-
jewska, H. (2005). Saccharomyces
boulardii in the prevention of
antibiotic-associated diarrhoea in
children: a randomized double-
blind placebo-controlled trial.
Aliment. Pharmacol. Ther. 21,
583–590.
Krämer, S., and Bischoff, S. C. (2006).
Therapeutic possibilities of pro-
biotics in antibiotic-related diar-
rhea. MMW Fortschr. Med. 148,
28–30.
Kumura, H., Tanoue, Y., Tsukahara, M.,
Tanaka,T., and Shimazaki,K. (2004).
Screening of dairy yeast strains for
probiotic applications. J. Dairy Sci.
87, 4050–4056.
Kurtzman, C. P., Fell, J. W., and
Boekhout, T. (2011a). “Definition,
classification and nomenclature of
the yeasts,” in The Yeasts a Taxo-
nomic Study 5th Edn, eds C. P. Kurtz-
man, J. W. Fell, and T. Boekhout
(Amsterdam: Elsevier Science), 3–9.
Kurtzman, C. P., Fell, J. W., and
Boekhout, T. (2011b). The Yeasts: A
Taxonomic Study. Elsevier. Available
at: http://books.google.ca/books?
id=yfg79rlIFIkC
Kurugöl, Z., and Koturoglu, G. (2005).
Effects of Saccharomyces boulardii in
children with acute diarrhoea. Acta
Paediatr. 94, 44–47.
Lammerding, A. M., Garcia, M. M.,
Mann, E. D., Robinson, Y., Dor-
ward, W. J., Truscott, R. B., et al.
(1988). Prevalence of Salmonella
and thermophilic Campylobacter in
fresh pork, beef, veal and poultry in
Canada. J. Food Prot. 51, 47–52.
Lewis, S. J., Potts, L. F., and Barry, R.
E. (1998). The lack of therapeu-
tic effect of Saccharomyces boulardii
in the prevention of antibiotic-
related diarrhoea in elderly patients.
J. Infect. 36, 171–174.
Li, J., Li, D., Gong, L., Ma, Y., He, Y.,
and Zhai, H. (2006). Effects of live
yeast on the performance, nutrient
digestibility, gastrointestinal micro-
biota and concentration of volatile
fatty acids in weanling pigs. Arch.
Anim. Nutr. 60, 277–288.
Line, J. E., Bailey, J. S., Cox, N. A.,
Stern, N. J., and Tompkins, T. (1998).
Effect of yeast-supplemented feed on
Salmonella and Campylobacter pop-
ulations in broilers. Poult. Sci. 77,
405–410.
Liu, S., and Tsao, M. (2010a). Biocon-
trol of spoilage yeasts and moulds
by Williopsis saturnus var. satur-
nus in yoghurt. Nutr. Food Sci. 40,
166–175.
Liu, S.-Q., and Tsao, M. (2010b).
Enhancing stability of lactic acid
bacteria and probiotics by Williop-
sis saturnus var. saturnus in fer-
mented milks. Nutr. Food Sci. 40,
314–322.
Liu, S.-Q., and Tsao, M. (2009a). Bio-
control of dairy moulds by antag-
onistic dairy yeast Debaryomyces
hansenii in yoghurt and cheese at
elevated temperatures. Food Control
20, 852–855.
Liu, S.-Q., and Tsao, M. (2009b).
Enhancement of survival of probi-
otic and non-probiotic lactic acid
bacteria by yeasts in fermented milk
under non-refrigerated conditions.
Int. J. Food Microbiol. 135, 34–38.
Liu, S.-Q., and Tsao, M. (2009c). Inhi-
bition of spoilage yeasts in cheese
by killer yeast Williopsis saturnus var.
saturnus. Int. J. Food Microbiol. 131,
280–282.
Llorente, P., Marquina, D., Santos, A.,
Peinado, J. M., and Spencer-Martins,
I. (1997). Effect of salt on the
killer phenotype of yeasts from olive
brines. Appl. Environ. Microbiol. 63,
1165–1167.
Lowes, K. F., Shearman, C. A., Payne, J.,
MacKenzie, D., Archer, D. B., Merry,
R. J., et al. (2000). Prevention of
yeast spoilage in feed and food by the
yeast mycocin HMK. Appl. Environ.
Microbiol. 66, 1066–1076.
Lyons, T. P., Jacques, K. A., and Daw-
son, K. A. (1993). “Miscellaneous
products from yeasts,” in The Yeasts,
2nd Edn, Vol. 5, eds A. H. Rose and
J. S. Harrison (London: Academic),
293–325.
Magliani, W., Conti, S., Frazzi, R.,
Ravanetti, L., Maffei, D. L., and
Polonelli, L. (2005). Protective anti-
fungal yeast killer toxin-like anti-
bodies. Curr. Mol. Med. 5, 443–452.
Magliani, W., Conti, S., Gerloni, M.,
Bertolotti, D., and Polonelli, L.
(1997). Yeast killer systems. Clin.
Microbiol. Rev. 10, 369–400.
Magliani, W., Conti, S., Travassos, L.
R., and Polonelli, L. (2008). From
yeast killer toxins to antibiobodies
and beyond. FEMS Microbiol. Lett.
288, 1–8.
Mansour-Ghanaei, F., Dehbashi, N.,
Yazdanparast, K., and Shafaghi, A.
(2003). Efficacy of Saccharomyces
boulardii with antibiotics in acute
amoebiasis. World J. Gastroenterol. 9,
1832–1833.
Marquina, D., Peres, C., Caldas, F. V.,
Marques, J. F., Peinado, J. M., and
Spencer-Martins, I. (1992). Charac-
terization of the yeast population in
olive brines. Lett. Appl. Microbiol. 14,
279–283.
Marquina, D., Santos, A., and Peinado,
J. M. (2002). Biology of killer yeasts.
Int. Microbiol. 5, 65–71.
Masih, E. I., and Paul, B. (2002). Secre-
tion of beta-1,3-glucanases by the
yeast Pichia membranifaciens and
its possible role in the biocontrol
of Botrytis cinerea causing grey
mold disease of the grapevine. Curr.
Microbiol. 44, 391–395.
Masih, E. I., Slezack-Deschaumes, S.,
Marmaras, I., Barka, E. A., Vernet,
G., Charpentier, C., et al. (2001).
Characterisation of the yeast Pichia
membranifaciens and its possible use
in the biological control of Botrytis
cinerea, causing the grey mould dis-
ease of grapevine. FEMS Microbiol.
Lett. 202, 227–232.
McFarland, L. V. (2007). Meta-analysis
of probiotics for the prevention
of traveler’s diarrhea. Travel Med.
Infect. Dis. 5, 97–105.
McFarland, L. V. (2010). System-
atic review and meta-analysis of
Saccharomyces boulardii in adult
patients. World J. Gastroenterol. 16,
2202–2222.
McFarland, L. V., Elmer, G. W.,
and McFarland, M. (2006). Meta-
analysis of probiotics for the preven-
tion and treatment of acute pediatric
diarrhea. Int. J. Probiotics Prebiotics
1, 63–76.
Mcfarland, L. V., Surawicz, C. M.,
Greenberg, R. N., Fekety, R., Elmer,
G. W., Moyer, K. A., et al. (1994).
A randomized placebo-controlled
trial combination with standard
antibiotics for Clostridium difficile
disease. J. Am. Med. Assoc. 271,
1913–1918.
Michalcáková, S., Sulo, P., and
Sláviková, E. (1993). Killer yeasts
of Kluyveromyces and Hansenula
genera with potential application
in fermentation and therapy. Acta
Biotechnol. 13, 341–350.
Millsap, K. W., Van Der Mei, H. C., Bos,
R., and Busscher, H. J. (1998). Adhe-
sive interactions between medically
important yeasts and bacteria. FEMS
Microbiol. Rev. 21, 321–336.
Morales-López, R., Auclair, E., Van
Immerseel, F., Ducatelle, R., García,
F., and Brufau, J. (2010). Effects of
different yeast cell wall supplements
added to maize- or wheat-based
diets for broiler chickens. Br. Poult.
Sci. 51, 399–408.
Narvhus, J. A., and Gadaga, T. H. (2003).
The role of interaction between
yeasts and lactic acid bacteria in
African fermented milks: a review.
Int. J. Food Microbiol. 86, 51–60.
Palpacelli, V., Ciani, M., and Rosini, G.
(1991). Activity of different “killer”
yeasts on strains of yeast species
undesirable in the food industry.
FEMS Microbiol. Lett. 68, 75–78.
Patterson, J. A., and Burkholder, K.
M. (2003). Application of prebiotics
and probiotics in poultry produc-
tion. Poult. Sci. 82, 627–631.
Pfeiffer, P., and Radler, F. (1984). Com-
parison of the killer toxin of sev-
eral yeasts and the purification of
a toxin of type K2. Arch. Microbiol.
137, 357–361.
Plein, K., and Hotz, J. (1993). Therapeu-
tic effects of Saccharomyces boulardii
on mild residual symptoms in a sta-
ble phase of Crohn’s disease with
special respect to chronic diarrhea –
a pilot study. Z. Gastroenterol. 31,
129–134.
Polonelli, L., Lorenzini, R., De
Bernardis, F., and Morace, G.
(1986). Potential therapeutic effect
of yeast killer toxin. Mycopathologia
96, 103–107.
Polonelli, L., Magliani, W., Cioci-
ola, T., Giovati, L., and Conti, S.
(2011). From Pichia anomala killer
toxin through killer antibodies to
killer peptides for a comprehensive
anti-infective strategy. Antonie Van
Leeuwenhoek 99, 35–41.
Pothoulakis, C. (2009). Review article:
anti-inflammatory mechanisms of
action of Saccharomyces boulardii.
Aliment. Pharmacol. Ther. 30,
826–833.
Pothoulakis, C., Kelly, C. P., Joshi, M.
A., Gao, N., O’Keane, C. J., Castagli-
uolo, I., et al. (1993). Saccharomyces
boulardii inhibits Clostridium diffi-
cile toxin A binding and enterotox-
icity in rat ileum. Gastroenterology
104, 1108–1115.
Pretorius, I. S. (2000). Tailoring wine
yeast for the new millennium: novel
approaches to the ancient art of
winemaking. Yeast 16, 675–729.
Pretorius, I. S., du Toit, M., and van
Rensburg, P. (2003). Designer yeasts
for the fermentation industry of the
21st century. Food Technol. Biotech-
nol. 41, 3–10.
Frontiers in Microbiology | Food Microbiology December 2012 | Volume 3 | Article 421 | 10
Hatoum et al. Antimicrobial properties of yeast
Psani, M., and Kotzekidou, P. (2006).
Technological characteristics of
yeast strains and their potential
as starter adjuncts in Greek-
style black olive fermentation.
World J. Microbiol. Biotechnol. 22,
1329–1336.
Qamar, A., Aboudola, S., Warny, M.,
Michetti, P., Pothoulakis, C., LaM-
ont, J. T., et al. (2001). Saccha-
romyces boulardii stimulates intesti-
nal immunoglobulin A immune
response to Clostridium difficile
toxin A in mice. Infect. Immun. 69,
2762–2765.
Rigothier, M. C., Maccario, J., and
Gayral, P. (1994). Inhibitory activ-
ity of Saccharomyces yeasts on the
adhesion of Entamoeba histolytica
trophozoites to human erythro-
cytes in vitro. Parasitol. Res. 80,
10–15.
Rodrigues, F., Ludovico, P., and Leão, C.
(2006). “Sugar metabolism in yeasts:
an overview of aerobic and anaero-
bic glucose catabolism,” in The Yeast
Handbook, eds. G. Péter and C. Rosa
(Berlin: Springer), 101–121.
Romano, P., Capece, A., and Jespersen,
L. (2006). “Taxonomic and ecolog-
ical diversity of food and bever-
age yeasts,” in The Yeast Handbook,
eds. A. Querol and G. Fleet (Berlin:
Springer), 13–53.
Rosini, G., and Cantini, M. (1987).
Killer character in Kluyveromyces
yeasts: activity on Kloeckera apic-
ulata. FEMS Microbiol. Lett. 44,
81–84.
Saint-Marc, T., Blehaut, H., Musial, C.,
and Touraine, T. (1995). Aids-related
diarrhea: a double-blind trial of
Saccharomyces boulardii. Sem. Hôsp.
Paris 71, 735–741.
Santos, A., and Marquina, D. (2004).
Ion channel activity by Pichia mem-
branifaciens killer toxin. Yeast 21,
151–162.
Sauerwein, H., Schmitz, S., and Hiss, S.
(2007). Effects of a dietary applica-
tion of a yeast cell wall extract on
innate and acquired immunity, on
oxidative status and growth perfor-
mance in weanling piglets and on the
ileal epithelium in fattened pigs. J.
Anim. Physiol. Anim. Nutr. (Berl.) 91,
369–380.
Sazawal, S., Hiremath, G., Dhingra,
U., Malik, P., Deb, S., and Black,
R. E. (2006). Efficacy of probiotics
in prevention of acute diarrhoea:
a meta-analysis of masked, ran-
domised, placebo-controlled trials.
Lancet Infect. Dis. 6, 374–382.
Schmitt, M. J., and Breinig, F. (2002).
The viral killer system in yeast: from
molecular biology to application.
FEMS Microbiol. Rev. 26, 257–276.
Séguy, N., Polonelli, L., Dei-Cas, E., and
Cailliez, J. C. (1998). Effect of a killer
toxin of Pichia anomala to Pneu-
mocystis. Perspectives in the control
of pneumocystosis. FEMS Immunol.
Med. Microbiol. 22, 145–149.
Seki, T., Choi, E.-H., and Ryu, D. (1985).
Construction of killer wine yeast
strain. Appl. Environ. Microbiol. 49,
1211–1215.
Sezer, A., Usta, U., and Cicin, I.
(2009). The effect of Saccharomyces
boulardii on reducing irinotecan-
induced intestinal mucositis and
diarrhea. Med. Oncol. 26, 350–357.
Spadaro, D., and Gullino, M. L. (2004).
State of the art and future prospects
of the biological control of posthar-
vest fruit diseases. Int. J. Food Micro-
biol. 91, 185–194.
Suharja, A. A. S., Henriksson, A.,
and Liu, S.-Q. (2012). Impact
of Saccharomyces cerevisiae on
viability of probiotic Lactobacillus
rhamnosus in fermented milk
under ambient conditions. J. Food
Process. Preserv. doi:10.1111/j.1745-
4549.2012.00780.x
Surawicz, C. M., Elmer, G. W., Speel-
man, P., McFarland, L. V., Chinn, J.,
and Van Belle, G. (1990). Preven-
tion of antibiotic-associated diar-
rhea by Saccharomyces boulardii: a
prospective study. Z. Gastroenterol.
28, 259–260.
Surawicz, C. M., McFarland, L. V.,
Greenberg, R. N., Rubin, M., Fekety,
R., Mulligan, M. E., et al. (2000).
The search for a better treat-
ment for recurrent Clostridium dif-
ficile disease: use of high-dose van-
comycin combined with Saccha-
romyces boulardii. Oxford University
Press. Available at: http://www.ncbi.
nlm.nih.gov/pubmed/11049785.
Suzuki, C., Ando, Y., and Machida, S.
(2001). Interaction of SMKT, a killer
toxin produced by Pichia farinosa,
with the yeast cell membranes. Yeast
8, 1471–1478.
Suzuki, C., and Shimma, Y. I. (1999).
P-type ATPase spf1 mutants show a
novel resistance mechanism for the
killer toxin SMKT. Mol. Microbiol.
32, 813–823.
Swanson, K. S., Grieshop, C. M.,
Flickinger, E. A., Bauer, L. L.,
Healy, H.-P., Dawson, K. A., et
al. (2002a). Supplemental fruc-
tooligosaccharides and mannano-
ligosaccharides influence immune
function, ileal and total tract nutri-
ent digestibilities, microbial popula-
tions and concentrations of protein
catabolites in the large bowel of dogs.
J. Nutr. 132, 980–989.
Swanson, K. S., Grieshop, C. M.,
Flickinger, E. A., Healy, H. P.,
Dawson, K. A., Merchen, N. R., et
al. (2002b). Effects of supplemen-
tal fructooligosaccharides plus man-
nanoligosaccharides on immune
function and ileal and fecal micro-
bial populations in adult dogs. Arch.
Tierernahr. 56, 309–318.
Tanyuksel, M., and Petri, W. A. (2003).
Laboratory diagnosis of amebiasis.
Society 16, 713–729.
Tasteyre, A., Barc, M.-C., Karjalainen,
T., Bourlioux, P., and Collignon,
A. (2002). Inhibition of in vitro
cell adherence of Clostridium difficile
by Saccharomyces boulardii. Microb.
Pathog. 32, 219–225.
Tempé, J. D., Steidel, A. L., Blehaut,
H., Hasselmann, M., Lutun, P.,
and Maurier, F. (1983). Prevention
of diarrhea administering Saccha-
romyces boulardii during continu-
ous enteral feeding. Sem. Hop. 59,
1409–1412.
Todd, B. E. N., Fleet, G. H., and Hen-
schke, P. A. (2000). Promotion of
autolysis through the interaction of
killer and sensitive yeasts: poten-
tial application in sparkling wine
production. Am. J. Enol. Vitic. 51,
65–72.
Valdés-Stauber, N., Scherer, S., and
Seiler, H. (1997). Identification of
yeasts and coryneform bacteria from
the surface microflora of brick
cheeses. Int. J. Food Microbiol. 34,
115–129.
Van Der Aa Kühle, A., and Jespersen,
L. (2003). The taxonomic posi-
tion of Saccharomyces boulardii as
evaluated by sequence analysis of
the D1/D2 domain of 26S rDNA,
the ITS1-5.8S rDNA-ITS2 region
and the mitochondrial cytochrome-
c oxidase II gene. Syst. Appl. Micro-
biol. 26, 564–571.
Van Der Aa Kühle,A.,Skovgaard,K., and
Jespersen, L. (2005). In vitro screen-
ing of probiotic properties of Sac-
charomyces cerevisiae var. boulardii
and food-borne Saccharomyces cere-
visiae strains. Int. J. Food Microbiol.
101, 29–39.
Van Dijken, J. P., and Scheffers, W.
A. (1986). Redox balances in the
metabolism of sugars by yeasts.
FEMS Microbiol. Lett. 32, 199–224.
van Heugten, E., Funderburke, D. W.,
and Dorton, K. L. (2003). Growth
performance, nutrient digestibility,
and fecal microflora in weanling
pigs fed live yeast. J. Anim. Sci. 81,
1004–1012.
Van Vuuren, H. J. J., and Jacobs, C.
J. (1992). Killer yeasts in the wine
industry: a review. Am. J. Enol. Vitic.
43, 119–128.
Vandenplas, Y., Brunser, O., and Sza-
jewska, H. (2009). Saccharomyces
boulardii in childhood. Eur. J. Pedi-
atr. 168, 253–265.
Viljoen, B. (2006). “Yeast ecolog-
ical interactions. Yeast’yeast,
yeast’bacteria, yeast’fungi inter-
actions and yeasts as biocontrol
agents,” in Yeasts in Food and Bev-
erages, eds. A. Querol and G. Fleet
(Berlin: Springer), 83–110.
Viljoen, B. C. (2001). The interaction
between yeasts and bacteria in dairy
environments. Int. J. Food Microbiol.
69, 37–44.
Villarruel, G., Rubio, D. M., Lopez, F.,
Cintioni, J., Gurevech, R., Romero,
G., et al. (2007). Saccharomyces
boulardii in acute childhood diar-
rhoea: a randomized, placebo-
controlled study. Acta Paediatr. 96,
538–541.
Walker, G. M., McLeod, A. H., and
Hodgson, V. J. (1995). Interactions
between killer yeasts and pathogenic
fungi. FEMS Microbiol. Lett. 127,
213–222.
Webster, J., and Weber, R. (2007).
Introduction to Fungi. Cambridge
University Press. Available at:
http://books.google.ca/books?id=
HZLXFi-om-0C
Weiler, F., and Schmitt, M. J. (2003).
Zygocin, a secreted antifungal toxin
of the yeast Zygosaccharomyces bailii,
and its effect on sensitive fun-
gal cells. FEMS Yeast Res. 3,
69–76.
Whelan, K. (2007). Enteral-tube-
feeding diarrhoea: manipulating the
colonic microbiota with probiotics
and prebiotics. Proc. Nutr. Soc. 66,
299–306.
White, J. H., Butler, A. R., and Stark,
M. J. R. (1989). Kluyveromyces lactis
toxin does not inhibit yeast adenylyl
cyclase. Nature 341, 666–668.
Wickner, R. B. (1996). Double-stranded
RNA viruses of Saccharomyces
cerevisiae. Microbiol. Rev. 60,
250–265.
Wijsman, M. R., Van Dijken, J. P.,
Van Kleeff, B. H., and Scheffers, W.
A. (1984). Inhibition of fermenta-
tion and growth in batch cultures
of the yeast Brettanomyces inter-
medius upon a shift from aero-
bic to anaerobic conditions (Custers
effect). Antonie Van Leeuwenhoek 50,
183–192.
Wyder, M., and Puhan, Z. (1999). Role
of selected yeasts in cheese ripening:
an evaluation in aseptic cheese curd
slurries. Int. Dairy J. 9, 3–10.
Xie, N., Zhou, T., and Li, B. (2012). Kefir
yeasts enhance probiotic potentials
of Lactobacillus paracasei H9: the
positive effects of coaggregation
between the two strains. Food Res.
Int. 45, 394–401.
www.frontiersin.org December 2012 | Volume 3 | Article 421 | 11
Hatoum et al. Antimicrobial properties of yeast
Yoshiuchi, K., Watanabe, M., and
Nishimura, A. (2000). Breeding
of a non-urea producing sake
yeast with killer character using a
kar1-1; mutant as a killer donor.
J. Ind. Microbiol. Biotechnol. 24,
203–209.
Young, T. W. (1981). The genetic
manipulation of killer character into
brewing yeast. J. Inst. Brew. 87,
292–295.
Young, T. W., and Yagiu, M. (1978). A
comparison of the killer character in
different yeasts and its classification.
Antonie Van Leeuwenhoek 44, 59–77.
Zhang, A. W., Lee, B. D., Lee, S. K., Lee,
K. W., An, G. H., Song, K. B., et
al. (2005). Effects of yeast (Saccha-
romyces cerevisiae) cell components
on growth performance, meat qual-
ity, and ileal mucosa development
of broiler chicks. Poult. Sci. 84,
1015–1021.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 06 August 2012; accepted: 21
November 2012; published online: 19
December 2012.
Citation: Hatoum R, Labrie S and Fliss I
(2012) Antimicrobial and probiotic prop-
erties of yeasts: from fundamental to novel
applications. Front. Microbio. 3:421. doi:
10.3389/fmicb.2012.00421
This article was submitted to Frontiers in
Food Microbiology, a specialty of Fron-
tiers in Microbiology.
Copyright © 2012 Hatoum, Labrie and
Fliss. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the orig-
inal authors and source are credited
and subject to any copyright notices
concerning any third-party graphics
etc.
Frontiers in Microbiology | Food Microbiology December 2012 | Volume 3 | Article 421 | 12
